Navigation Links
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.
Date:5/22/2013

NEW YORK, May 22, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NasdaqGS: AMAG -News).  The investigation focuses on whether the Company and its executives violated federal securities laws.

On May 22, 2013, Shares of AMAG dropped $2.69 or 10.73% during intraday trading after the company announced in regulatory filing that it has been made aware by Takeda Pharmaceutical Company Limited, the exclusive product distributor of ferumoxytol in Switzerland, that it is recalling one specific batch of Rienso, ferumoxytol, from the Swiss market. This decision is based on a cluster of four post-marketing adverse event reports in Switzerland concerning hypersensitivity reactions of varying severity following the administration of Rienso from this batch.  One of these cases included a report of a fatality.

If you are aware of any facts relating to this investigation, or purchased shares of AMAG, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.  Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein 212-697-6484
info@bgandg.com

 


'/>"/>
SOURCE Bronstein, Gewirtz & Grossman, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
2. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
4. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
5. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
6. Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets
7. Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
9. Physician-Patient Alliance for Health & Safety Announces Four Essentials for Safety for Patients Receiving Opioids
10. Edgemont Capital Completes Sale Of Vince & Associates Clinical Research
11. ELNs, Data Analytics, Knowledge Management: Trends, Challenges & Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
(Date:12/8/2016)... PUNE, India , December 8, 2016 According ... (Diagnostic (Heart, Pulse, BP, Sleep, Fetal), Therapeutic (Pain, Insulin)), End Use (Sports, ... to 2021", published by MarketsandMarkets, the global market, in terms of value, ... in 2016, at a CAGR of 18.0% during the forecast period. ... ...
(Date:12/8/2016)... 8, 2016  Haemonetics Corporation (NYSE: HAE ) ... System), an innovative software suite designed to help customers drive ... launch of NextGen DMS 4 improves core features and introduces ... per liter of plasma collected, enhancing quality and regulatory compliance ... ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... , ... California Senate Bill (SB) 863, signed into law in 2012, may ... 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , a study ... medical payments per claim in California decreased 4 percent in 2013 and then 3 ...
(Date:12/8/2016)... ... December 08, 2016 , ... Dickinson Insurance ... offices headquartered in Little Rock, has initiated a charity drive to provide support ... Foundation to End Senior Hunger, Arkansas ranks first in senior hunger statewide, third ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Coppin Insurance ... owners and families in and around the Cape Coral area, is embarking on a ... Food Bank of Southwest Florida. , The Harry Chapin Food Bank of Southwest Florida ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again ... that it is one of the early adopters completing EU-U.S. Privacy Shield Certification from ... to provide companies on both sides of the Atlantic with a mechanism to comply ...
Breaking Medicine News(10 mins):